Brixton Biosciences Strengthens Board with Industry Veterans as Company Advances Towards Commercialization of Reneurx™ Nerve-Selective Therapy for Pain Associated with Knee Osteoarthritis

CAMBRIDGE, Mass., August 18, 2026--Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced the appointment of three new members to its Board of Directors: founding CEO of Alnylam Pharmaceuticals and RNAi pioneer, John Maraganore, Ph.D.; CEO of Bausch + Lomb and biopharma deal-maker, Brent Saunders; and former General Manager, Philadelphia 76ers, Elton Brand